TUCSON, Ariz., Oct. 1, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, announced the availability of the HTG EdgeSeq Immuno-Oncology Assay (research use only) for digitally measuring the mRNA expression of 549 genes implicated in the host immune response to tumors. Automated on the HTG EdgeSeq system, HTG EdgeSeq Immuno-Oncology Assay couples HTG's proprietary nuclease protection chemistry with next-generation sequencing (NGS).
"With this new immuno-oncology assay, researchers can measure the expression levels of drug targets, determine tumor infiltrate composition, and assess total immune cell composition using just a single section of FFPE tissue," stated Chris Roberts, HTG's Senior Vice President of Marketing and Medical Innovation. "We believe the expanding trend in the development of immuno-oncology therapies will continue, and this new assay can be a valuable tool in the research of tumor biomarkers in tissue and liquid biopsies."
"HTG Molecular is proud to be at the forefront of this new product category," commented TJ Johnson, HTG's Chief Executive Officer. "We continue to believe that the combination of HTG's extraction free sample and library preparation chemistry automated on the HTG EdgeSeq system with NGS quantitation is providing our customers with powerful new capabilities," Mr. Johnson added.
About HTG Molecular Diagnostics:
Headquartered in Tucson, Arizona, HTG's mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with our business and capabilities of our technology. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with trends in market development; market acceptance of our technical solution and/or products; molecular profiling research and development activities; our ability to successfully commercialize our products; and our ability to manufacture our products to meet demand. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the Quarter ended June 30, 2015. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: email@example.com TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: firstname.lastname@example.org
Source:HTG Molecular Diagnostics